logo
Sign in

INRLF Stock Price, Chart, Stats & News

Valneva SE
Save

Valneva SE (INRLF) does not currently pay a dividend.

639.11M
Market cap
–
Current P/E
3.35x
Forward P/E

INRLF chart

About

Health care
Sector
Biotechnology
Industry

Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli.

Similar securities

Based on sector and market capitalization

Report issue